Publications by authors named "Yuzo Nagamitsu"
Introduction: Hypoxia occurs in the first trimester of placental development and is implicated in the regulation of trophoblast differentiation. Prolonged hypoxic conditions in the placenta are related to the development of preeclampsia. MicroRNAs (miRNAs) are noncoding, single-stranded RNAs that modulate gene expression by targeting messenger RNA.
View Article and Find Full Text PDFMicroRNA (miRNA) expression is altered in cancer cells and is associated with the development and progression of various types of cancer. Accordingly, miRNAs may serve as diagnostic or prognostic biomarkers in cancer patients. In this study, we attempted to analyze circulating exosomal miRNA in patients with cervical cancer.
View Article and Find Full Text PDFArticle Synopsis
- - The study aimed to assess which postoperative therapy, either dienogest or goserelin, is more effective in preventing the recurrence of endometriosis after surgery, as there's no established consensus on hormone therapy treatments.
- - Researchers conducted a 24-month randomized study with 198 endometriosis patients divided into three groups: those receiving dienogest, those receiving goserelin, and a non-treatment group, measuring recurrence rates, menstrual pain, and side effects.
- - Results showed that while both medications improved pain, only dienogest significantly reduced recurrence compared to the non-treatment group, making it a more favorable long-term option over goserelin, which had more noticeable side effects.
Hypoxia occurs during development of cervical cancer and is considered to correlate with its invasion. Hypoxia mediates tumor cells to have more invasive property in a variety of cancers. Urokinase plasminogen activator receptor (uPAR) which mediates invasion is considered to be induced by hypoxia.
View Article and Find Full Text PDFObjectives: This is a multicenter, collaborative study to accumulate cases of small cell carcinoma of the uterine cervix (SmCC), to clarify its clinical and clinicopathologic features and prognosis, and to obtain findings to establish future individualized treatment.
Methods: At medical centers participating in the Kansai Clinical Oncology Group/Intergroup, patients diagnosed with SmCC between 1997 and 2007 were enrolled. Clinicopathologic features and prognosis were retrospectively evaluated in patients with SmCC diagnosed at a central pathologic review.